靶向测序与相对突变剂量无创产前检测胎儿母源性β地中海贫血突变遗传的可行性研究
该可行性研究在东南亚产前门诊采集样本,对49例已确认父源性β地中海贫血突变遗传的样本采用巢式PCR扩增后测序,并以相对突变剂量判定胎儿是否继承母源野生型或突变等位基因;48/49例获得母源等位基因分类(98.0%),44/48例与结果一致(91.7%),灵敏度87.5%(95%CI 67.6-97.3%),特异度95.8%(95%CI 78.9-99.9%)。
要点
- 相对突变剂量在48/49例样本中成功分类母源等位基因遗传(98.0%)。
- 与已知结果一致44/48例(91.7%),出现1例假阳性和3例假阴性。
- 灵敏度87.5%(95%CI 67.6-97.3%),特异度95.8%(95%CI 78.9-99.9%)。
核心结论
- 相对突变剂量检测母源性β地中海贫血突变遗传具有临床应用的潜力,序贯方法或可应用于其他单基因病。
研究设计与样本
- 采用产前门诊采集样本的可行性研究,对象为双方均携带四种常见β地中海贫血突变之一或HbE突变、有受累胎儿风险的夫妇。
- 对49例已确认继承父源性β地中海贫血突变的样本进行巢式聚合酶链反应(PCR)扩增后测序,并以相对突变剂量判定胎儿继承母源野生型或突变等位基因。
主要发现
- 48/49例样本获得母源等位基因遗传分类(98.0%)。
- 44/48例判定一致(91.7%),出现1例假阳性和3例假阴性。
- 母源基因型遗传的总体灵敏度为87.5%(95%CI 67.6-97.3%),特异度为95.8%(95%CI 78.9-99.9%)。
关键数值与推荐
- 胎儿继承母源野生型等位基因判为「未受累」,继承母源突变等位基因判为β地中海贫血「受累」。
临床怎么用
- 作者认为相对突变剂量检测母源性β地中海贫血突变遗传具有临床应用的潜力,序贯方法或可应用于其他单基因病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether targeted sequencing and relative mutation dosage can be used to diagnose correctly inheritance of maternal β-thalassaemia mutations in cell-free DNA. DESIGN: Feasibility study using samples collected in a prenatal clinic. SETTING: South East Asia. POPULATION: Couples where both partners were known to be carriers of one of four common β-thalassaemia mutations or an HbE mutation, and therefore at risk of carrying a fetus affected with β-thalassaemia. METHODS: 49 samples previously identified as having inherited a paternal β-thalassaemia mutation were amplified using nested polymerase chain reaction (PCR), and then sequencing. Relative mutation dosage was used to classify the fetus as having inherited the wild-type or mutant maternal allele. MAIN OUTCOME MEASURES: Classification of the fetus as 'unaffected' (if the maternal wild-type allele was inherited) or 'affected' with β-thalassaemia (if the maternal mutant allele was inherited). RESULTS: A classification for inheritance of maternal allele was obtained in 48/49 samples (98.0%). A concordant call was made in 44/48 cases (91.7%): one false-positive and three false-negatives were obtained. Thus, we had an overall sensitivity of 87.5% [95% confidence interval (CI) 67.6-97.3%] and a specificity of 95.8% (95% CI 78.9-99.9%) for inheritance of maternal genotype. CONCLUSIONS: RMD for detection of inheritance of maternal β-thalassaemia mutations has potential for clinical use. Our sequential approach could be applied to other single-gene disorders. TWEETABLE ABSTRACT: NIPT for β-thalassaemia achieved using nested-PCR followed by relative mutation dosage.
引用
- Xiong L, Barrett AN, Hua R, et al. Non-invasive prenatal testing for fetal inheritance of maternal β-thalassaemia mutations using targeted sequencing and relative mutation dosage: a feasibility study. BJOG. 2018. PMID: 29211324. doi:10.1111/1471-0528.15045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。